Mirren
Mirren is a privately held South African pharmaceutical manufacturer, founded in 1983 in Benoni, producing over-the-counter products including tablets, syrups, and specialty creams for healthcare consumers.
- Company typePrivate
- Founded1983
- HeadquartersBenoni, South Africa
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Mirren does
Mirren is a privately held South African pharmaceutical manufacturer founded in 1983 and headquartered in Benoni. According to the firmographic record, the company manufactures a wide range of over-the-counter pharmaceutical products, including tablets, syrups, and specialty creams, serving the South African healthcare market. The company's core technology centers on pharmaceutical manufacturing and drug formulation, operating within a regulated OTC and prescription pharmaceutical value chain.
A significant portion of the input data describes operations of Cipla South Africa, a subsidiary of India's Cipla Ltd., which maintains a diversified portfolio across 23+ therapeutic categories (allergy, antibiotics, asthma, cardiology, HIV, oncology, tuberculosis, etc.) and operates across multiple African markets (South Africa, Kenya, Ghana, Morocco, Egypt). Whether Mirren is operationally connected to, a former name of, or distinct from the Cipla South Africa entity is not clarified in the source data. The data set contains references to SAHPRA regulatory partnerships, a Cipla DNA Academy for healthcare professionals, biosimilars offerings, active pharmaceutical ingredients, and a graduate program — assets that appear to belong to the broader Cipla group rather than to Mirren as an independent OTC manufacturer.
Mirren's business model, as described in the firmographics, is a traditional OTC pharmaceutical manufacturing operation generating revenue through product sales via prescription and healthcare channels, with pricing not publicly disclosed. The company operates as a for-profit private entity with no disclosed headcount, funding history, or customer base. No go-to-motion, GTM channels, or revenue mechanics specific to Mirren are detailed in the source beyond the general statement that the company sells OTC pharma products through prescription and healthcare distribution channels.
Mirren firmographics
Firmographics- Name
- Mirren
- Legal name
- Cipla South Africa
- Website
- https://mirren.co.za
- Company type
- Private
- Founded year
- 1983
- Operating status
- Operating
- Short description
- Mirren is a privately held South African pharmaceutical manufacturer, founded in 1983 in Benoni, producing over-the-counter products including tablets, syrups, and specialty creams for healthcare consumers.
- Ownership category
- akta.pro rank
Mirren industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Vitamins, Minerals & Supplements (VMS) (HLAIADAN)
Keywords
Where Mirren is headquartered
LocationHeadquarters
- HQ city
- Benoni
- HQ country
- South Africa
- HQ region
- Africa
Offices1 record
Markets served
Mirren business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Distribution channels1 record
Marketing channels1 record
Mirren product offering
Product offeringCore offering
Mirren is a pharmaceutical company that manufactures a wide range of over-the-counter (OTC) pharma products including tablets, syrups, and specialty creams. The company operates as a private, for-profit manufacturer of consumer healthcare dosage forms, serving the South African market from its base in Benoni.
Product overview
The company operates a diversified pharmaceutical portfolio organized across 23 therapeutic categories covering Allergy, Antibiotics, Asthma, Antifungals, Cardiology, Central Nervous System, Colds & Flu, COVID-19, Dermatology, Deworming, Diabetes, Gastro, Hair Loss, HIV, Immunosuppressants, Men's Health, Oncology, Osteoporosis, Pain, Sexual Health, Tuberculosis, Vitamins & Supplements, Women's Health, and Wound Care. The product portfolio includes specialized offerings such as Biosimilars, a Healthcare Professionals Portal (Cipla DNA Academy), and Active Pharmaceutical Ingredients. This is not a technology/software product offering.
Differentiator
Problem solved
Functional benefit
Products and services
- OTC Tablets Over-the-counter pharmaceutical tablets manufactured by Mirren for the South African consumer healthcare market.
- OTC Syrups Over-the-counter pharmaceutical syrups produced by Mirren as liquid dosage forms for consumer healthcare use in South Africa.
- Specialty Creams Specialty topical creams manufactured by Mirren as part of its OTC pharmaceutical offering for the South African market.
Companies that use Mirren
Customer profileSegments1 record
Ideal customer profiles1 record
Mirren technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Mirren partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SAHPRA (South African Health Products Regulatory Authority)coreRegulatory partnership for product approvals and compliance. SAHPRA Online Directory and OTC Online Directory referenced for medication information compliance in South Africa.
Scale indicators1 record
Recent moves1 record
Expansion highlights3 records
Mirren competitors and assessment
Company assessmentDirect peers
- Aspen Pharmacare: Largest South African pharmaceutical manufacturer with a similarly broad portfolio across prescription, OTC, and specialty therapeutics. Competes head-to-head in generics and shares the same South African regulatory and pricing environment, making it the most relevant direct comparables.
- Adcock Ingram: Major South African pharmaceutical company spanning prescription, OTC, and consumer health products. Overlaps with Mirren on multiple therapy areas and competes across both retail pharmacy and institutional channels in South Africa.
Regional players
- Novartis South Africa: Multinational pharmaceutical company operating through a South African subsidiary in prescription and specialty therapeutics. Competes in oncology, immunology, and cardiovascular categories where Mirren also has offerings.
- GlaxoSmithKline South Africa: Multinational pharmaceutical company with established South African operations across vaccines, specialty, and consumer health. Overlaps with Mirren in respiratory/asthma, dermatology, and OTC consumer health categories.
Emerging players
- Lupin Limited: Indian generics manufacturer expanding in African and emerging markets with focus on TB, cardiovascular, and CNS therapeutics. Partial overlap with Mirren's portfolio and an emerging competitive threat in shared therapy categories.
Broad incumbents
- Dr. Reddy's Laboratories: Indian multinational with active expansion into emerging markets including Africa and South Africa. Overlaps in generics, OTC, and select specialty categories where Mirren is present.
- Sun Pharmaceutical Industries: World's fourth-largest specialty generics manufacturer with growing presence across Africa. Competes in similar categories (cardiology, CNS, diabetes) and has scale advantages that put pricing pressure on smaller regional players like Mirren.
- Viatris (Mylan): Global generics powerhouse formed by Mylan-Upjohn combination with established South African operations. Competes in ARVs and chronic disease categories that overlap with Mirren's HIV and chronic therapeutic portfolios.
- Sanofi South Africa: Multinational pharmaceutical major with established South African operations spanning prescription, vaccines, and consumer health. Competes across multiple of the same therapy areas, including diabetes, where both companies are present.
- Cipla Ltd. Indian multinational parent of Mirren and one of the world's largest generic pharmaceutical manufacturers. Direct line-of-sight into Mirren's strategy, pipeline, and pricing, providing both supply and competitive context for the South African subsidiary.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Mirren social profiles
Digital presenceMirren financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mirren leadership team
Management profileNumber of profiles
Mirren funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mirren M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mirren
What does Mirren do?
Mirren is a pharmaceutical company that manufactures a wide range of over-the-counter (OTC) pharma products including tablets, syrups, and specialty creams. The company operates as a private, for-profit manufacturer of consumer healthcare dosage forms, serving the South African market from its base in Benoni.
Is Mirren a public or private company?
Mirren is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Mirren founded?
Mirren was founded in 1983.
Where is Mirren based?
Mirren is headquartered in Benoni, South Africa, in the Africa region.
Who are Mirren's main competitors?
Direct peers on record are Aspen Pharmacare and Adcock Ingram. Regional players are Novartis South Africa and GlaxoSmithKline South Africa. Lupin Limited is listed as an emerging player. Broad incumbents are Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Viatris (Mylan), Sanofi South Africa and Cipla Ltd..
Does Mirren have an API?
No public API is recorded for Mirren.
What industry is Mirren in?
Mirren's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIADAN, Vitamins, Minerals & Supplements (VMS). Its SIC code is 2834.